Navigation Links
Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
Date:8/19/2007

Dr. David S. Smith to Head Regulatory and Quality Affairs

DUBLIN, Calif., Aug. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Audrey F. Jakubowski, Ph.D., Chief Regulatory and Quality Officer will retire effective today. Dr. Jakubowski's primary responsibilities have been transitioned to David S. Smith, Ph.D., who earlier this year joined SuperGen as Vice President, Regulatory and Quality Affairs.

"Dr. Jakubowski has been extremely instrumental in guiding and growing SuperGen's regulatory and quality efforts over the years," said Dr. James Manuso, President and CEO. "A valued colleague, Audrey created and nurtured a highly effective organization and approach to regulatory affairs and quality management that the Company will continue under Dr. David Smith's leadership."

Dr. Smith, 52, joined SuperGen in March 2007. Prior to joining SuperGen, Dr. Smith was Senior Director, Regulatory Strategy at Wyeth Consumer Healthcare. His responsibilities included obtaining new product registrations on a global level, US marketed product support, and providing scientific and regulatory guidance to business development initiatives. From 1996 to 2000, Dr. Smith served as Regulatory Affairs Program Director at Roche Pharma. Dr. Smith began his regulatory career in 1987 at Schering-Plough, where he focused on the development and registration of oncology and biotechnology products. During his tenure at Schering-Plough, he concentrated on European Union activities and major markets outside of the U.S. Dr. Smith's training includes a post-doctoral fellowship and research in biochemical genetics at the Roche Institute of Molecular Biology. He received a Ph.D. in pharmacology from Wayne State University School of Medicine, and a B.S. in Biophysics, also from Wayne State University.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development Tel: (925) 560-2845

Tel: (925) 560-0100

E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. State technology chief endorses IT audit recommendations
2. Fusion 2007: CA chief says IT complexity raises risk
3. Web-Based Learning Developed under new Chief Education Officer
4. BD IMag Human Regulatory T Lymphocyte Separation Set for Isolation of Treg Cells
5. Emergence of Internet video is changing the regulatory landscape
6. To attract investment, convince manufacturers that regulatory reform is real
7. Support Regulatory Change to Boost Wisconsins Biotech Sector
8. A Simple and Rapid Technique to Purify High-Quality Midiprep DNA
9. Generate High-Quality, Directional Plasmid cDNA Libraries
10. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
11. Using the Agilent 2100 bioanalyzer for quality control of protein samples prior to MS-analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Cancer ... exhibiting in booth 513 at the Association of Community Cancer Centers (ACCC) 43rd ... 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations to share ...
(Date:3/29/2017)... 2017 Research and Markets has announced the ... - Industry Forecast to 2025" report to their offering. ... The Global Agricultural ... 7.8% over the next decade to reach approximately $825.4 million by ... and forecasts for all the given segments on global as well ...
(Date:3/29/2017)... MO , March 29, 2017 /PRNewswire/ - The ... its partners Nordion, a business of Sterigenics International, and ... (LAR) has been submitted to the U.S. Nuclear Regulatory ... domestic U.S. production of molybdenum-99 (Mo-99). Once operational, production ... half of U.S. demand for Mo-99, which currently must ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Biotechnology: Emerging Technologies and Global Markets" report to their ... ... next generation DNA sequencing, biochips, RNA interference, synthetic biology tools ... seeds; and biologicals. These technologies and products are ...
Breaking Biology Technology:
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
Breaking Biology News(10 mins):